A MYD88 mutation test looks for an acquired change in the MYD88 gene, most often the p.L265P variant, in bone marrow, blood, lymph node tissue, cerebrospinal fluid, or another tumor sample. The result is especially useful when doctors are evaluating Waldenström macroglobulinemia, also called lymphoplasmacytic lymphoma with an IgM monoclonal protein. More than 90% of typical Waldenström cases carry MYD88 L265P, but the mutation is not unique to that disease and is not required for diagnosis. It can also occur in IgM monoclonal gammopathy of undetermined significance, primary central nervous system lymphoma, vitreoretinal lymphoma, and subsets of other B-cell lymphomas. A positive result supports the suspected diagnosis only when the pathology and clinical setting fit. A negative result may reflect true wild-type disease, low tumor content, an uncommon MYD88 variant, or a test that examined only L265P. Treatment implications also depend on CXCR4 status, symptoms, disease site, prior therapy, and the specific drug being considered.
- MYD88 L265P is present in most Waldenström macroglobulinemia cases, but it does not diagnose the disease by itself.
- A positive result can also occur in IgM MGUS and several other B-cell lymphomas.
- A negative result should be checked against specimen quality, assay sensitivity, and whether non-L265P variants were covered.
- MYD88 status can influence expectations for Bruton tyrosine kinase inhibitor therapy, but it is not the only treatment factor.
- Bone marrow is commonly tested in Waldenström macroglobulinemia; cerebrospinal or vitreous fluid may be tested for selected CNS or eye lymphomas.
Table of Contents
- What MYD88 Does
- When Testing Is Used
- Specimens and Test Methods
- Understanding Positive and Negative Results
- MYD88 in Waldenström Macroglobulinemia
- Other Lymphomas and Differential Diagnosis
- Treatment and Monitoring
- Limitations and Next Steps
What MYD88 Does
MYD88 makes an adaptor protein used by toll-like receptors and the interleukin-1 receptor family. These receptors help immune cells respond to infection and inflammation. After a receptor is activated, MYD88 helps assemble a signaling complex that turns on NF-κB and other pathways. The signal normally rises and falls in a controlled way.
The p.L265P mutation changes one amino acid in a region needed for protein interactions. The altered protein can form an active signaling complex without the usual upstream trigger, supporting survival of the abnormal B-cell clone. Reports may write the finding as MYD88 c.794T>C (p.Leu265Pro), L265P, or L252P, depending on the transcript numbering convention. The report should identify the transcript and protein notation so apparently different labels are not mistaken for different variants.
In lymphoma testing, MYD88 is usually a somatic biomarker. A mutation detected in tumor-rich marrow, lymph node, cerebrospinal fluid, or vitreous fluid generally reflects the malignant clone rather than inherited DNA. Routine testing does not determine family cancer risk. Rare germline MYD88 changes cause immune disorders, but those conditions are biologically and clinically separate from an adult lymphoma test.
The mutation’s diagnostic value comes from its frequency pattern. It is very common in Waldenström macroglobulinemia and some lymphomas arising in immune-privileged sites, while it is uncommon in several competing diagnoses. Still, no frequency is 100%. The mutation can support a diagnosis, but morphology, immunophenotype, serum protein studies, and clinical features determine whether the whole picture fits.
MYD88 is often tested with CXCR4 in Waldenström macroglobulinemia. CXCR4 mutations, frequently frameshift or nonsense variants resembling those in WHIM syndrome, can coexist with MYD88 L265P and may affect disease behavior and response kinetics to some therapies. A broad panel may also report CD79B, ARID1A, TP53, or other changes, but their routine clinical roles vary.
When Testing Is Used
The most common reason to order MYD88 testing is an IgM monoclonal gammopathy with bone marrow lymphoplasmacytic infiltration. The test helps distinguish Waldenström macroglobulinemia or lymphoplasmacytic lymphoma from marginal zone lymphoma, IgM plasma-cell myeloma, chronic lymphocytic leukemia, and other small B-cell neoplasms. It is most informative when the biopsy is difficult to classify or the specimen is limited.
Waldenström macroglobulinemia requires an IgM monoclonal protein and a compatible clonal lymphoplasmacytic marrow infiltrate. The amount of IgM alone does not establish the diagnosis, and MYD88 positivity alone does not either. A person with IgM MGUS may carry the same mutation but lacks the tumor burden, symptoms, or marrow features needed for active lymphoma.
Other common uses include:
- suspected primary central nervous system lymphoma in a brain biopsy or cerebrospinal fluid sample;
- suspected vitreoretinal lymphoma using ocular fluid;
- selected diffuse large B-cell lymphomas, especially extranodal or activated B-cell-like tumors;
- difficult small B-cell lymphoma differentials;
- confirmation that two disease sites may be clonally related;
- research or selected monitoring applications using highly sensitive assays.
The test should answer a defined clinical question. Screening healthy people for MYD88 L265P is not recommended. Testing a serum IgM level without examining the marrow cannot separate IgM MGUS from Waldenström macroglobulinemia. Likewise, a positive cerebrospinal-fluid result needs correlation with cytology, flow cytometry, imaging, symptoms, and the possibility of blood contamination.
Clinicians may order a focused L265P assay when the main question is Waldenström macroglobulinemia. A broader lymphoma panel is preferable when the differential is wide or a non-L265P variant could matter. The choice balances speed, sensitivity, specimen size, and the need for additional biomarkers.
Specimens and Test Methods
Bone marrow aspirate is the usual specimen for Waldenström macroglobulinemia, often tested alongside the core biopsy and flow cytometry. Peripheral blood can be used when circulating tumor cells are sufficient, but sensitivity may be lower. Lymph node or extranodal tissue is appropriate for a mass-forming lymphoma. Cerebrospinal fluid and vitreous fluid require methods designed for very small cell-free or cellular samples.
| Method | Typical use | Strength | Limitation |
|---|---|---|---|
| Allele-specific PCR | Focused L265P detection | Fast and highly sensitive | Does not find other MYD88 variants |
| Digital PCR | Low-level mutation detection or quantification | Very high analytic sensitivity | Usually targets a known variant |
| Targeted NGS | Lymphoma panel | Finds multiple genes and uncommon MYD88 variants | May be less sensitive in low-tumor samples |
| Sanger sequencing | Sequence confirmation in tumor-rich samples | Direct sequence readout | Low sensitivity for small clones |
| Cell-free DNA assay | CSF, vitreous, or plasma in selected settings | May work when few intact cells are present | Clinical validation is specimen- and disease-specific |
The report may include variant allele fraction. VAF reflects the proportion of tested DNA molecules carrying the mutation, not the percentage of marrow occupied by lymphoma and not the serum IgM concentration. Low tumor purity, normal-cell admixture, copy-number changes, and technical factors alter VAF. A very low result near the assay cutoff may need repeat or orthogonal confirmation.
Preanalytic handling is especially important for fluid specimens. Cerebrospinal-fluid cells deteriorate quickly, and vitreous samples are tiny. Laboratories may split material among cytology, flow cytometry, cytokine testing, and molecular analysis. Coordinating with pathology before collection helps preserve enough sample for the highest-priority tests.
A report should state whether the assay tested only L265P or sequenced a larger region. “MYD88 not detected” from an L265P-only PCR does not exclude another pathogenic MYD88 mutation. The detection limit and specimen adequacy statement are equally important.
Understanding Positive and Negative Results
A positive MYD88 L265P result supports an MYD88-driven B-cell clone. In a patient with IgM monoclonal protein and lymphoplasmacytic marrow morphology, it strongly supports Waldenström macroglobulinemia. In cerebrospinal or vitreous fluid, it can support lymphoma involving those sites when clinical and laboratory findings agree.
The same positive result is not specific. It may occur in IgM MGUS, primary CNS lymphoma, vitreoretinal lymphoma, testicular DLBCL, cutaneous leg-type DLBCL, and subsets of other lymphomas. The site and phenotype determine the interpretation. It should never be translated automatically into “Waldenström positive.”
A not-detected result may mean the tumor is MYD88 wild type. Approximately a small minority of otherwise typical Waldenström cases lack L265P. These cases deserve careful pathology review because some may represent another B-cell neoplasm. A negative result may also arise from low tumor content, hemodiluted marrow, degraded DNA, limited assay coverage, or therapy that reduced the clone below detection.
A non-L265P MYD88 variant needs variant-specific interpretation. Some alterations activate the pathway, while others are uncertain or benign. A broad sequencing report may classify the finding as pathogenic, likely pathogenic, or a variant of uncertain significance. A VUS should not be used as if it were L265P without supporting evidence.
An equivocal low-level result can be repeated on the same extract, tested with another method, or confirmed in a better specimen. Blood contamination can complicate fluid results, although a tumor mutation in cell-free DNA can still be informative. The pathologist should comment on limitations rather than forcing a binary label.
The result should be integrated with serum protein electrophoresis, immunofixation, quantitative immunoglobulins, free light chains, complete blood count, marrow morphology, immunophenotype, imaging, and symptoms. An isolated molecular finding cannot distinguish an asymptomatic precursor state from lymphoma requiring treatment.
MYD88 in Waldenström Macroglobulinemia
Waldenström macroglobulinemia is a lymphoplasmacytic lymphoma that produces monoclonal IgM. Symptoms can result from marrow infiltration, enlarged nodes or spleen, or the physical and immune effects of IgM. Anemia, fatigue, hyperviscosity, neuropathy, cryoglobulinemia, cold agglutinin hemolysis, and kidney or skin problems may occur. Some people have no symptoms and are monitored without therapy.
MYD88 L265P is present in more than 90% of typical cases. Its presence helps separate Waldenström macroglobulinemia from IgM plasma-cell myeloma, which usually lacks MYD88 L265P and may show plasma-cell genetics such as t(11;14). Marginal zone lymphoma can occasionally carry MYD88, so spleen, lymph-node pattern, immunophenotype, and marrow architecture remain important.
MYD88 status is not a treatment trigger. Therapy begins for clinically significant symptoms or organ effects, not because the mutation is positive or the IgM crosses a single universal number. Hyperviscosity symptoms—new visual disturbance, severe headache, confusion, mucosal bleeding, or shortness of breath—can require urgent assessment and plasmapheresis. The numerical IgM level does not perfectly predict viscosity in every person.
CXCR4 testing can refine the molecular profile. MYD88-mutated/CXCR4-wild-type and MYD88-mutated/CXCR4-mutated disease may respond differently to certain Bruton tyrosine kinase inhibitors, particularly in speed and depth. MYD88-wild-type disease may have lower response rates to some covalent BTK inhibitor monotherapies and may prompt consideration of another regimen. These are population-level patterns, not guarantees.
The mutation may also help distinguish progression of an established Waldenström clone from a new unrelated lymphoma. Transformation to aggressive DLBCL can occur, and a new biopsy is essential because treatment changes substantially. MYD88 status alone cannot diagnose transformation.
Other Lymphomas and Differential Diagnosis
Primary central nervous system lymphoma frequently carries MYD88 L265P, often with CD79B mutations. Detecting the variant in a brain biopsy supports the diagnosis. In selected patients, highly sensitive cerebrospinal-fluid testing can add evidence when biopsy is risky or when monitoring is being studied, but it does not replace tissue whenever safe, definitive biopsy is possible.
Primary vitreoretinal lymphoma is closely related biologically to CNS lymphoma. MYD88 testing on vitreous fluid can improve diagnostic confidence when cytology is scant or distorted. False negatives occur because the specimen contains few malignant cells and prior corticosteroids can lower yield. Ocular inflammation has many nonmalignant causes, so a positive molecular result should be reviewed by ocular oncology and hematopathology teams.
In DLBCL, MYD88 is enriched in activated B-cell-like molecular subtypes and lymphomas of immune-privileged sites, including CNS and testis. It may coexist with CD79B and contribute to chronic active B-cell receptor signaling. Routine treatment is not selected from MYD88 alone; the full DLBCL classification, stage, and clinical trial evidence remain central.
Some marginal zone lymphomas and rare other B-cell neoplasms carry MYD88. Conversely, many lymphoplasmacytic-appearing disorders are MYD88 wild type. Immunophenotype, morphology, paraprotein type, cytogenetics, and disease distribution prevent overdiagnosis.
When the differential includes plasma-cell myeloma, pathologists consider plasma-cell markers, cyclin D1, CD56, light-chain restriction, lytic bone disease, renal dysfunction, calcium, and characteristic cytogenetics. A tumor molecular profile is supportive, but the disease name emerges from integrated evidence rather than one mutation.
Treatment and Monitoring
MYD88 L265P activates a pathway that includes Bruton tyrosine kinase, helping explain why BTK inhibitors can be effective in Waldenström macroglobulinemia. Available options may include covalent BTK inhibitors, anti-CD20-based chemoimmunotherapy, proteasome-inhibitor combinations, and other regimens. Selection depends on age, heart rhythm, bleeding risk, neuropathy, kidney function, disease tempo, prior treatment, MYD88/CXCR4 profile, access, and patient priorities.
A positive mutation does not mean a BTK inhibitor is mandatory. Some patients prefer fixed-duration chemoimmunotherapy rather than continuous oral therapy. Others have comorbidities that make one class less suitable. MYD88-wild-type patients can still respond to treatment, and the molecular result should not be used to deny active therapy.
Routine response monitoring relies primarily on symptoms, examination, blood counts, IgM, serum protein studies, and imaging or marrow when indicated. IgM can temporarily rise after anti-CD20 therapy, an “IgM flare,” without immediate proof of progression. Conversely, BTK inhibitors can lower IgM before marrow disease disappears. Response criteria account for multiple measures.
Highly sensitive quantitative MYD88 assays are being studied for disease burden and residual disease, but they are not universally standardized as a sole routine monitoring tool. A rising molecular signal without clinical or laboratory progression should be interpreted cautiously. The same assay, specimen type, and laboratory improve comparability if serial testing is used.
For CNS or vitreoretinal lymphoma, local disease assessment, imaging, ophthalmic examination, cytology, and flow cytometry remain important. Molecular clearance may be informative in selected protocols, but treatment decisions should follow disease-specific guidance.
Limitations and Next Steps
The most frequent error is treating MYD88 L265P as a disease label. It is a highly useful contextual biomarker, not a pathognomonic result. Another common error is assuming a negative test excludes Waldenström macroglobulinemia without checking whether the specimen contained tumor or whether the assay covered only one variant.
Additional limitations include tumor heterogeneity, small specimens, variable analytic sensitivity, and uncertainty about the clinical meaning of rare variants. Prior therapy may reduce tumor DNA. Decalcified marrow tissue can damage nucleic acids. Blood is convenient but may be insensitive in patients with little circulating disease.
After a result, ask:
- What specimen was tested, and was tumor content adequate?
- Did the assay test only L265P or all relevant MYD88 regions?
- Does the marrow or tissue morphology support Waldenström macroglobulinemia, another lymphoma, or IgM MGUS?
- Was CXCR4 tested, and would it change treatment expectations?
- Is treatment needed because of symptoms, or is observation appropriate?
- Does MYD88 status influence the recommended regimen in my specific situation?
- Would another specimen or an orthogonal method clarify a negative or low-level result?
- Are there urgent hyperviscosity symptoms that require immediate care?
Keep the complete molecular and pathology reports. They should document variant notation, method, detection limit, VAF when available, specimen, and integrated diagnosis. If the result and clinical picture disagree, expert review is more valuable than repeating the same narrow test without addressing specimen quality or the differential diagnosis.
Clinical scenarios that change the interpretation
A patient with a small IgM monoclonal protein, normal hemoglobin, no symptoms, and minimal marrow involvement may have IgM MGUS even when MYD88 L265P is detected. The mutation confirms a clone but does not create an indication for treatment. Monitoring focuses on symptoms, blood counts, IgM trend, and examination rather than trying to eradicate a molecular finding.
A patient with anemia, symptomatic hyperviscosity, bulky nodes, neuropathy caused by the IgM protein, or organ dysfunction can have treatment-requiring Waldenström macroglobulinemia. Here, MYD88 helps confirm biology and may inform drug selection, but urgency comes from the complication. Plasmapheresis can lower circulating IgM quickly in hyperviscosity, while systemic therapy controls the cells producing it. Plasmapheresis alone is not durable lymphoma treatment.
In suspected CNS lymphoma, a positive MYD88 result in cerebrospinal fluid is strongest when the sample also has clonal B cells, abnormal cytology, compatible MRI findings, or another lymphoma marker. A negative fluid test is common when the lesion does not shed DNA into the sampled compartment. Corticosteroids can shrink CNS lymphoma rapidly and reduce biopsy yield, so treatment timing and tissue planning should be coordinated whenever clinically safe.
In ocular disease, a low-cellularity vitreous sample may be divided among several tests. Asking the ophthalmologist and laboratory to coordinate before the procedure can prevent all material from being consumed by cytology. Interleukin-10 measurements, flow cytometry, MYD88 testing, and cytomorphology provide complementary evidence.
The phrase “MYD88 wild type” deserves particular care in an apparent Waldenström case. The team should confirm that the assay was sensitive enough, that the marrow aspirate was not hemodiluted, and that the lymphoma is truly lymphoplasmacytic rather than marginal zone or IgM myeloma. If the diagnosis remains sound, wild-type disease is real and can carry different treatment-response patterns. It is not a laboratory failure by definition.
For long-term records, note whether the patient’s mutation was detected in marrow, blood, or another compartment and whether CXCR4 was sequenced. If future therapy is considered, this baseline can explain why a later plasma assay is negative despite persistent marrow disease or why response kinetics differ from typical expectations.
IgM and marrow burden do not always move in parallel. A treatment can rapidly lower IgM while substantial marrow lymphoma remains, or IgM can transiently rise after rituximab without true progression. Response should therefore be assigned with standardized criteria rather than one laboratory value. New anemia also requires evaluation for bleeding, hemolysis, nutritional deficiency, kidney disease, or treatment effect.
Neuropathy deserves a specific workup because diabetes, vitamin deficiency, amyloidosis, anti-MAG antibodies, cryoglobulins, and medication toxicity can produce similar symptoms. Demonstrating MYD88 in marrow confirms the lymphoma clone but does not prove that every symptom is caused by it. Treatment is most effective when the complication and its mechanism are clearly linked.
Treatment decisions should also account for atrial fibrillation, hypertension, bleeding medicines, infection risk, and the need for procedures because these factors can influence BTK inhibitor choice. Vaccination and infection-prevention plans belong in the same discussion. A molecularly appropriate drug can still be a poor personal choice when comorbidities create avoidable risk.
A pharmacist should review CYP3A interactions, anticoagulants, supplements, and adherence before oral therapy begins. This practical review can prevent avoidable toxicity, underexposure, and confusion when IgM changes unexpectedly.
Low-level MYD88 findings need assay-aware interpretation. A highly sensitive targeted method may detect a small clone that broad sequencing misses, while a weak signal can also approach the laboratory’s validated detection limit. The report’s specimen, sensitivity, and quality notes therefore belong in the clinical interpretation.
References
- Waldenström Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management 2025 (Review)
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management 2023 (Review)
- Mutational landscape in Waldenström macroglobulinemia and its clinical significance 2024 (Cohort Study)
- Primary large B-cell lymphomas of immune-privileged sites 2024 (Review)
- MYD88 Mutation Analysis 2025 (Official Test Guide)
Disclaimer
This article provides general education and cannot diagnose Waldenström macroglobulinemia or another lymphoma. MYD88 results must be integrated with pathology, IgM studies, symptoms, and specialist assessment. New visual changes, confusion, severe headache, significant bleeding, or other possible hyperviscosity symptoms require urgent medical evaluation.
